The latest price target for Biohaven (NYSE:BHVN) was reported by Cantor Fitzgerald on December 17, 2024. The analyst firm set a price target for $0.00 expecting BHVN to fall to within 12 months (a possible -100.00% downside). 40 analyst firms have reported ratings in the last year.

The latest analyst rating for Biohaven (NYSE:BHVN) was provided by Cantor Fitzgerald, and Biohaven reiterated their overweight rating.

There is no last upgrade for Biohaven

The last downgrade for Biohaven Ltd happened on August 19, 2022 when Piper Sandler changed their price target from N/A to N/A for Biohaven Ltd.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Biohaven, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Biohaven was filed on December 17, 2024 so you should expect the next rating to be made available sometime around December 17, 2025.

While ratings are subjective and will change, the latest Biohaven (BHVN) rating was a reiterated with a price target of $0.00 to $0.00. The current price Biohaven (BHVN) is trading at is $36.26, which is out of the analyst’s predicted range.